European Commission approves AbbVie's Rinvoq (upadacitinib) for the treatment of psoriatic arthritis and ankylosing spondylitis

AbbVie

25 January 2021 - Approval is supported by data from three pivotal clinical studies in psoriatic arthritis and ankylosing spondylitis where Rinvoq met all primary and met key secondary endpoints with a safety profile consistent with that seen in rheumatoid arthritis.

AbbVie today announced that the European Commission has approved Rinvoq (upadacitinib, 15 mg), an oral, once daily selective and reversible JAK inhibitor for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. Rinvoq may be used as monotherapy or in combination with methotrexate. Rinvoq is also indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. 

The European Commission approval is supported by data from the three pivotal clinical trials SELECT-PsA 1, SELECT-PsA 2 and SELECT-AXIS 1, demonstrating Rinvoq's efficacy across multiple measures of disease activity.

Read AbbVie press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , Europe